<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In B-cell lineage <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>), the clonal rearrangements of the immunoglobulin heavy chain gene locus (IgH), can be used as a molecular marker for the detection of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients in complete remission may still harbor leukemic cells undetectable by conventional methods such as light-microscopic examination, immunophenotyping and cytogenetics </plain></SENT>
<SENT sid="2" pm="."><plain>30 children with <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> were screened at diagnosis by polymerase chain reaction (PCR) for their IgH gene repertoire </plain></SENT>
<SENT sid="3" pm="."><plain>7/30 patients were extensively studied using patient-specific oligonucleotide probes derived from the sequence analysis of bone marrow (BM) samples at diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>210 PCR products from follow-up BM samples corresponding to these 7 patients were hybridized with the appropriate clone-specific probe in order to detect <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> with high sensitivity and specificity </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients were in morphological remission during and after therapy </plain></SENT>
<SENT sid="6" pm="."><plain>25/30 patients were PCR positive at diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain>4/7 patients who were examined for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> had detectable disease in various periods after diagnosis </plain></SENT>
<SENT sid="8" pm="."><plain>Molecular signs of residual cells can persist for a long time during and after therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Long term follow-up of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> could determine the period of therapy and predict relapse, indicating therapeutic interventions </plain></SENT>
</text></document>